Gastric Cancer
Despite advances in chemotherapy, first-line treatment for advanced G/GEJ adenocarcinoma yields a median overall survival of approximately one year. The large majority of gastric cancer patients are HER2-negative and therefore ineligible f…
1 sources - 5 claims
Despite advances in chemotherapy, first-line treatment for advanced G/GEJ adenocarcinoma yields a median overall survival of approximately one year. The large majority of gastric cancer patients are HER2-negative and therefore ineligible for trastuzumab. The inability to benefit from either HER2-targeted or PD-1-based immunotherapy in a large proportion of gastric cancer patients creates the rationale for adding anti-angiogenic therapy to broaden immune responsiveness.